AquilaGen Presenting at ASHG 2026

Our co-founders, Marie-Joe Dib and Zen Jelenje, will be attending the American Society of Human Genetics (ASHG) Annual Meeting 2026 in Montreal, where they will be presenting our latest research on TMPRSS6.

What can human genetics tell us about the benefits and potential risks of inhibiting TMPRSS6?

Our work examines human genetic evidence for the therapeutic potential of TMPRSS6 inhibition, investigating its potential to reduce liver disease risk while evaluating possible safety liabilities that could shape its development as a therapeutic target.

The findings highlight how human genetics can help inform target validation, assess potential efficacy and safety, and guide the development of genetics-informed therapeutic strategies.

Poster presentation details

  • Presenter: Marie-Joe Dib
  • Poster board: 8405F, Exhibit Hall
  • Date: Friday, October 23, 2026
  • Time: 2:30–4:30 pm EDT
  • Session: Statistical Genetics and Genetic Epidemiology

We look forward to connecting with researchers, clinicians and industry leaders working in human genetics, liver disease, target validation and genetics-informed drug discovery.

Share:

View other resources

scientist-works-lab-with-computer-screen-displaying-dna-it
Our co-founders, Marie-Joe Dib and Zen Jelenje, will...
10
Oct
Precision in biotech: a person inserts a DNA sample in a tube into a sequencing machine
On 15 September 2026, AquilaGen Co-Founder Dr Marie-Joe...
10
Sep

Ask us about your targets

We'll bring the evidence Whether you have a specific asset in mind or want to understand how genetic intelligence could strengthen your program or portfolio – let’s talk.